Allurion to Participate in the Jefferies London Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK

6. S
7. GAP
8. DG
9. ULTA
10. NVDA

Get Alerts ALUR Hot Sheet

Price: $1.45 +6.62%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the Jefferies London Healthcare Conference taking place on November 14-16, 2023 in London. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Wednesday, November 15, 2023 at 9:30 a.m. GMT, and will be available for investor 1x1 meetings.

A live webcast of the event will be available on the Allurion website, under Events & Presentations. You can also register for the live webcast here.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan, whether it is gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.